Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Amplifon is the global leader in hearing care retail with ~9,200 points of sale across 26 countries, primarily in Europe (Italy, France, Germany, Netherlands) and North America. The company operates through a direct-to-consumer model combining retail stores, audiological services, and hearing aid distribution, serving an aging demographic with recurring device replacement cycles (typically 4-6 years). Stock performance is driven by same-store sales growth, store network expansion, reimbursement policy changes in key markets, and the company's ability to capture market share in a fragmented $15B+ global industry.
Amplifon generates revenue through direct retail sales of hearing aids (average selling price €1,500-2,500 per device) combined with audiological testing and fitting services. The business model relies on high-touch customer service, proprietary fitting software, and relationships with insurance providers and national health systems. Gross margins appear compressed in reported financials (8.3%) likely due to accounting treatment of audiologist labor as COGS rather than SG&A. True product margins on devices are estimated at 40-50%, with profitability driven by store productivity (customers per location), average transaction value, and operating leverage from corporate infrastructure spread across growing store base. Competitive advantages include scale purchasing from manufacturers (Sonova, Demant, WS Audiology), brand recognition in local markets, and proprietary customer databases enabling targeted marketing to aging populations.
Same-store sales growth rates in core European markets (Italy, France, Germany) - indicates market penetration and pricing power
Store network expansion pace and new market entry announcements - signals growth runway
Reimbursement policy changes in France, Italy, and Netherlands where government/insurance coverage affects demand elasticity
M&A activity and bolt-on acquisitions to consolidate fragmented regional markets
Competitive pricing pressure from online hearing aid entrants (Audicus, Eargo) and OTC regulatory changes in US market
OTC hearing aid regulatory approval in US (FDA approved 2022, implemented 2024-2025) enabling direct consumer purchase without audiologist, disintermediating retail model and compressing margins on lower-end devices
Technological disruption from smartphone-connected hearing aids and AI-powered fitting algorithms reducing need for in-person audiologist visits and store network
Reimbursement policy deterioration in European markets facing fiscal pressure - France '100% Santé' reform (2021) capped prices, Italy and Germany could follow
Demographic tailwinds (aging population) partially offset by later adoption as device quality improves and stigma reduces, extending replacement cycles beyond historical 4-6 years
Vertical integration by manufacturers (Sonova, Demant) expanding own retail networks and reducing wholesale partnerships with Amplifon
Online pure-plays (Audicus, hear.com) capturing price-sensitive customers with 40-50% lower prices and telehealth fitting services
Costco hearing aid centers leveraging membership base and bulk purchasing to offer premium devices at mid-market prices, particularly threatening in US market
Elevated debt levels (1.53x D/E, €1.4B estimated net debt) limiting financial flexibility during downturn or if cash generation disappoints
Low current ratio (0.52x) indicates working capital pressure and reliance on operating cash flow to fund ongoing operations and capex
Goodwill and intangible assets from serial acquisitions create impairment risk if acquired stores underperform or market conditions deteriorate
Pension obligations in mature European markets (Italy, Germany) represent off-balance sheet liabilities sensitive to discount rate changes
low-to-moderate - Hearing loss is age-related and non-discretionary, providing defensive characteristics during recessions. However, out-of-pocket spending (where insurance doesn't cover) is sensitive to consumer confidence and discretionary income. Estimated 60-70% of European sales have some insurance/government reimbursement, reducing cyclicality. Premium device upgrades and accessories show more economic sensitivity than basic hearing aids.
Rising rates have dual impact: (1) Negative - increases financing costs on €1.4B net debt (estimated from 1.53x D/E), compressing margins and reducing M&A capacity; (2) Negative - higher mortgage rates and living costs reduce discretionary spending on out-of-pocket hearing aid purchases, particularly in US market where insurance coverage is lower; (3) Negative - valuation multiple compression as investors rotate from growth to higher-yielding alternatives. Store expansion capex (~€300M annually based on reported figures) becomes more expensive to finance.
Moderate - Company relies on acquisition financing for bolt-on deals in fragmented markets. Tighter credit conditions limit M&A-driven growth strategy and increase refinancing risk on existing debt. Consumer credit availability affects higher-end device purchases in markets with limited insurance coverage. Current 1.53x D/E suggests manageable but elevated leverage requiring consistent cash generation.
value - Current 1.0x P/S and 7.6x EV/EBITDA suggest deep value territory following -37% stock decline. Attracts contrarian investors betting on operational turnaround, margin recovery, and demographic tailwinds. Defensive healthcare characteristics appeal to income-focused investors despite current financial stress. Not a growth stock given -0.6% revenue decline and margin compression.
moderate-to-high - Recent performance shows significant drawdowns (-37% 1-year, -19% 6-month) indicating elevated volatility. European small-cap healthcare stocks typically exhibit beta of 0.8-1.2 to broader market. Company-specific execution risk, M&A integration challenges, and regulatory uncertainty in hearing aid markets create event-driven volatility around earnings and policy announcements.